Overview
Medical technology firm's Q4 revenue grew 4% yr/yr, driven by U.S. console sales
Gross margin improved to 68.2% from 58.4% in prior-year quarter
Company announced $5 mln private placement and Rendiatech acquisition
Outlook
Nuwellis aims to integrate Rendiatech acquisition and expand cardiorenal portfolio in 2026
Company plans to progress development of Vivian, a pediatric solution, in 2026
Nuwellis focuses on driving consistent commercial execution and deeper utilization in 2026
Result Drivers
CONSOLE SALES - 208% increase in U.S. console sales drove Q4 revenue growth
GROSS MARGIN IMPROVEMENT - Gross margin rose to 68.2% due to improved pricing and product mix
HEART FAILURE AND PEDIATRICS - Heart Failure revenue increased 48% and Pediatrics increased 16% in Q4
Company press release: ID:nGNX77jFp2
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q4 Sales | Beat | $2.42 mln | $2.31 mln (1 Analyst) |
Q4 EPS | -$1.50 | ||
Q4 Net Income | -$2.42 mln | ||
Q4 Gross Profit | $1.65 mln | ||
Q4 Income from Operations | -$2.44 mln | ||
Q4 Pretax Profit | -$2.42 mln |
Analyst Coverage
The one available analyst rating on the shares is "hold"
The average consensus recommendation for the advanced medical equipment & technology peer group is "buy."
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)